1887

Abstract

The black yeast has been isolated in respiratory samples from people with cystic fibrosis (CF). However, adequate detection may require longer incubation periods than the current UK national standard for CF respiratory samples. Furthermore, it is unclear whether isolation of is associated with poorer clinical outcomes in CF.

does not cause clinically significant lung disease in CF adults.

To evaluate differences in clinical outcomes over a 12 month period and during acute pulmonary exacerbations between CF adults with and without untreated .

Incubation times for respiratory samples on Sabouraud dextrose agar with chloramphenicol (SABC) plates at a large regional adult CF centre were extended from 2 to 7 days over a 1 month period. The number of patients from whom was isolated, and the length of incubation time prior to isolation, were recorded. Outcomes of treatment of exacerbations with intravenous antibiotics but in the absence of concomitant antifungal therapy were compared between those with and without , as were changes in lung function and body mass index (BMI) over a 12 month period.

Extended incubation unmasked the presence of in 22 of 132 patients; all isolations occurred after >48 h of incubation. Patients who isolated had lower rates of isolation (=0.02) and higher rates of non-tuberculous mycobacteria isolation (=0.03), and were more likely to be prescribed a long-term antifungal medication (=0.03), but had no differences in age, sex, baseline lung function or body mass index (BMI). There were no differences in response to treatment of acute exacerbations between patients with and without , or in change in forced expiratory volume in 1 s (FEV1), BMI and number of exacerbations over 12 months of follow-up.

is not associated with worse clinical outcomes in CF. Given potential side effects and drug interactions, routine targeting of with antifungals during acute exacerbations is not advised.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001431
2022-05-20
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/71/5/jmm001431.html?itemId=/content/journal/jmm/10.1099/jmm.0.001431&mimeType=html&fmt=ahah

References

  1. UK Cystic Fibrosis Registry UK Cystic Fibrosis Registry Annual Data Report 2019; 2019 https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources accessed 1 April 2021
  2. Speirs JJ, van der Ent CK, Beekman JM. Effects of Aspergillus fumigatus colonization on lung function in cystic fibrosis. Curr Opin Pulm Med 2012; 18:632–638 [View Article] [PubMed]
    [Google Scholar]
  3. Bakare N, Rickerts V, Bargon J, Just-Nübling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46:19–23 [View Article] [PubMed]
    [Google Scholar]
  4. Lebecque P, Leonard A, Huang D, Reychler G, Boeras A et al. Exophiala (Wangiella) dermatitidis and cystic fibrosis - Prevalence and risk factors. Med Mycol 2010; 48 Suppl 1:S4–9 [View Article] [PubMed]
    [Google Scholar]
  5. Schwarz C, Bouchara J-P, Buzina W, Chrenkova V, Dmeńska H et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia 2018; 183:7–19 [View Article] [PubMed]
    [Google Scholar]
  6. Engel TGP, Slabbers L, de Jong C, Melchers WJG, Hagen F et al. Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients - A Dutch, multicentre study. J Cyst Fibros 2019; 18:221–226 [View Article] [PubMed]
    [Google Scholar]
  7. Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 1992; 151:344–346 [View Article] [PubMed]
    [Google Scholar]
  8. Radonjic A, Pakhale S, Aaron SD, Earlam K, Gaudet E et al. Organizing pneumonia secondary to Exophiala dermatitidis in cystic fibrosis: A case report. J Cyst Fibros 2020; 19:e33–e35 [View Article] [PubMed]
    [Google Scholar]
  9. de Jong CCM, Slabbers L, Engel TGP, Yntema JB, van Westreenen M et al. Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: A nationwide study. Med Mycol 2020; 58:859–866 [View Article] [PubMed]
    [Google Scholar]
  10. The UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group Laboratory Standards for Processing Microbiological Samples from People with Cystic Fibrosis; 2010 https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/Laboratory%20standards.pdf accessed 1 April 2021
  11. Hong G, Miller HB, Allgood S, Lee R, Lechtzin N et al. Use of selective fungal culture media increases rates of detection of fungi in the respiratory tract of cystic fibrosis patients. J Clin Microbiol 2017; 55:1122–1130 [View Article] [PubMed]
    [Google Scholar]
  12. Kondori N, Gilljam M, Lindblad A, Jönsson B, Moore ERB et al. High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency. J Clin Microbiol 2011; 49:1004–1009 [View Article] [PubMed]
    [Google Scholar]
  13. Kondori N, Lindblad A, Welinder-Olsson C, Wennerås C, Gilljam M. Development of IgG antibodies to Exophiala dermatitidis is associated with inflammatory responses in patients with cystic fibrosis. J Cyst Fibros 2014; 13:391–399 [View Article] [PubMed]
    [Google Scholar]
  14. Burgel PR, Paugam A, Hubert D, Martin C. Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infect Drug Resist 2016; 9:229–238 [View Article] [PubMed]
    [Google Scholar]
  15. van der Meer R, Touw DJ, Heijerman HGM. Prevention of drug-related complications in cystic fibrosis. Curr Opin Pulm Med 2019; 25:666–673 [View Article] [PubMed]
    [Google Scholar]
  16. Mills R, Rautemaa-Richardson R, Wilkinson S, Patel L, Maitra A et al. Impact of airway Exophiala spp. on children with cystic fibrosis. J Cyst Fibros 2021; 20:702–707 [View Article] [PubMed]
    [Google Scholar]
  17. Singh A, Ralhan A, Schwarz C, Hartl D, Hector A. Fungal pathogens in CF airways: leave or treat?. Mycopathologia 2018; 183:119–137 [View Article] [PubMed]
    [Google Scholar]
  18. Renner S, Nachbaur E, Jaksch P, Dehlink E. Update on respiratory fungal infections in cystic fibrosis lung disease and after lung transplantation. J Fungi (Basel) 2020; 6:381 [View Article] [PubMed]
    [Google Scholar]
  19. Klasinc R, Riesenhuber M, Bacher A, Willinger B. Invasive fungal infection caused by Exophiala dermatitidis in a patient after lung transplantation: case report and literature review. Mycopathologia 2019; 184:107–113 [View Article] [PubMed]
    [Google Scholar]
  20. Packeu A, Lebecque P, Rodriguez-Villalobos H, Boeras A, Hendrickx M et al. Molecular typing and antifungal susceptibility of Exophiala isolates from patients with cystic fibrosis. J Med Microbiol 2012; 61:1226–1233 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001431
Loading
/content/journal/jmm/10.1099/jmm.0.001431
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error